GRCE Stock Price | Grace Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

Grace Therapeutics, Inc. • GRCE

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Grace Therapeutics, Inc.

Ticker

GRCE

Trading on

NASDAQ

ISIN

US00439U1043

Industry

Biotechnology

Sector

Healthcare

CEO

Prashant Kohli

Headquarters

103 Carnegie Center, Princeton, NJ, United States, 08540

Employees

Website

gracetx.com

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Metrics

BasicAdvanced

Market cap

$61.6M

P/E ratio

EPS

-$0.31

Dividend Yield

0.00%

Beta

0.76

Forward P/E ratio

2.17

EBIDTA

$-11.2M

Ex dividend date

Price & volume

Market cap

$61.6M

Average daily volume

0.3M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

2.17

PEG ratio

Trailing P/E

Price to sales

197.75

Price to book

0.94

Earnings

EPS

-$0.31

EPS estimate (current quarter)

-$0.39

EPS estimate (next quarter)

-$0.49

EBITDA

$-11.2M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

0.76

52-week High

$4.65

52-week Low

$1.75

50-day moving average

$3.75

200-day moving average

$3.27

Short ratio

3.48

Short %

2.97%

Management effectiveness

ROE (TTM)

-10.22%

ROA (TTM)

-10.84%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

14.1M

Float

9.8M

Insiders %

27.06%

Institutions %

28.00%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$11.51

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

$0.05

-$0.40

112.55%

Q1 • 25Beat

-$0.21

-$0.31

31.82%

Q2 • 25Beat

-$0.06

-$0.34

82.56%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-0.9M

-∞%

Q3 • 25

$0M

$-3.2M

-∞%

Q4 • 25

NaN%

238.64%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$66.6M

$3.8M

5.64%

Q3 • 25

$68.5M

$3.6M

5.25%

Q4 • 25

2.87%

-4.31%

-6.98%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-3.2M

$0M

$-0M

$-3.2M

Q3 • 25

$-2.2M

$0M

$4M

$-2.2M

Q4 • 25

-29.68%

-525,557.61%

-29.68%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Grace Therapeutics, Inc. share?

Grace Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Grace Therapeutics, Inc. have?

Grace Therapeutics, Inc. currently has 14.1M shares.

Does Grace Therapeutics, Inc. pay dividends?

No, Grace Therapeutics, Inc. doesn't pay dividends.

What is Grace Therapeutics, Inc. 52 week high?

Grace Therapeutics, Inc. 52 week high is $4.65.

What is Grace Therapeutics, Inc. 52 week low?

Grace Therapeutics, Inc. 52 week low is $1.75.

What is the 200-day moving average of Grace Therapeutics, Inc.?

Grace Therapeutics, Inc. 200-day moving average is $3.27.

Who is Grace Therapeutics, Inc. CEO?

The CEO of Grace Therapeutics, Inc. is Prashant Kohli.

How many employees Grace Therapeutics, Inc. has?

Grace Therapeutics, Inc. has 6 employees.

What is the market cap of Grace Therapeutics, Inc.?

The market cap of Grace Therapeutics, Inc. is $61.6M.

What is the P/E of Grace Therapeutics, Inc.?

The current P/E of Grace Therapeutics, Inc. is null.

What is the EPS of Grace Therapeutics, Inc.?

The EPS of Grace Therapeutics, Inc. is -$0.31.

What is the PEG Ratio of Grace Therapeutics, Inc.?

The PEG Ratio of Grace Therapeutics, Inc. is null.

What do analysts say about Grace Therapeutics, Inc.?

According to the analysts Grace Therapeutics, Inc. is considered a buy.